Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 2:34 AM
Ignite Modification Date: 2025-12-25 @ 2:34 AM
NCT ID: NCT00608634
Eligibility Criteria: DISEASE CHARACTERISTICS: * Resident of Pima or adjoining Southern Arizona county * Patients outside of Pima County are also eligible * Sun damaged skin as judged by the study physician and quantifiable, clinically diagnosed, and visible actinic keratoses (AK) on both dorsal forearms, with at least two AK on each arm * AK lesions must not be clustered, confluent, or too numerous to count accurately * Presence of AK on sites other than the test area allowed * No significant inflammation or irritation of the skin of the upper extremities that is not clinically diagnosed as sun damage or AK * Patients must agree to limit sun exposure as much as possible and may continue their normal pattern of sunscreen use PATIENT CHARACTERISTICS: Inclusion criteria: * Females must not be of childbearing potential, and therefore must be post-menopausal or surgically sterile by hysterectomy * Not pregnant or nursing Exclusion criteria: * Concurrent skin malignancy or disorder of the upper extremities * Patients with Squamous cell carcinoma or basal cell carcinoma in an area other than the test area are eligible upon excision of the Squamous cell carcinoma or basal cell carcinoma * Patients who are immunosuppressed by virtue of medication or disease * Serious concurrent illness that could interfere with study regimen * Invasive cancer within the past 5 years PRIOR CONCURRENT THERAPY: * At least 30 days since prior topical medications to the skin of the upper extremities except for emollients or sunscreens * At least 30 days since prior and no concurrent mega-doses of vitamins, defined as any of the following: * More than 5 times the recommended daily allowance * More than 5 capsules of multivitamins * 400 IU of vitamin E * 200 μg of selenium * 1 gm of vitamin C * At least 6 months since prior and no concurrent therapy for squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) anywhere in the test area (i.e., the forearms or hands) * Treatment for Squamous cell carcinoma or basal cell carcinoma on sites other than the test area is allowed * At least 4 weeks since prior surgical biopsy, surgical excision, or cryotherapy for AK in the test area and the sites must have healed * At least 6 months since prior topical treatment (e.g., 5-fluorouracil or imiquimod) for AK * No concurrent therapy that may interfere with clinical evaluations * No concurrent topical drug treatment (e.g., retinoids, aminolevulinic acid, diclofenac sodium, imiquimod, or fluorouracil) to any area of skin, including test area * No concurrent enrollment in another clinical trial * No concurrent topical citrus peel or consumption of citrus peel * No chemotherapy for cancer within the past 5 years
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT00608634
Study Brief:
Protocol Section: NCT00608634